The concordance of changes between S100A9 protein levels in liver and serum and its hepatic mRNA levels suggests that it may be useful as a reliable biomarker for the development of NAFLD, and it may possess the ability to differentiate different phenotypes of NAFLD. Here, S100A9 is linked to metabolic dysfunction-associated steatotic liver disease.